BioGaia AB: Year-end report January – December 2022
FOURTH QUARTER 2022 · Net sales amounted to SEK 274.3 million (206.2), an increase of SEK 68.1 million,...
Read moreFOURTH QUARTER 2022 · Net sales amounted to SEK 274.3 million (206.2), an increase of SEK 68.1 million,...
Read moreBioGaia's (NASDAQ: BIOG) financial report for the fourth quarter and full year of 2022 will be published at approximately...
Read moreTHIRD QUARTER 2022 · Net sales amounted to SEK 257.7 million (173.8), an increase of SEK 83.9 million,...
Read moreBioGaia's (NASDAQ: BIOG) financial report for the third quarter 2022 will be published at approximately 8:00 AM CEST...
Read moreBioGaia and Skinome have collaborated on the research and development of a product with live bacteria that can improve skin...
Read moreBioGaia is developing probiotic products and expanding its product portfolio with new bacterial strains, developed together with the wholly-owned...
Read moreSECOND QUARTER 2022 · Net sales amounted to SEK 288.1 million (203.1), an increase of SEK 85.0 million,...
Read moreAll news regarding BioGaia and our field of expertise can be found here, as well as official press releases from the company.